Your browser doesn't support javascript.
loading
CDH1 methylation analysis in invasive lobular breast carcinomas with and without gene mutation.
González-Martínez, Silvia; Kajabova, Viera Horvathova; Pérez-Mies, Belén; Carretero-Barrio, Irene; Caniego-Casas, Tamara; Sarrió, David; Moreno-Bueno, Gema; Gión, María; Perez-García, José; Cortés, Javier; Smolkova, Bozena; Palacios, José.
Afiliação
  • González-Martínez S; "Contigo Contra el Cáncer de la Mujer" Foundation, 28010, Madrid, Spain.
  • Kajabova VH; Molecular Pathology of Cancer Group, Ramón y Cajal Health Research Institute (IRYCIS), 28034, Madrid, Spain.
  • Pérez-Mies B; Centre for Biomedical Research in Cancer Networks (CIBERONC), Carlos III Health Institute, 28029, Madrid, Spain.
  • Carretero-Barrio I; Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 84505, Bratislava, Slovakia.
  • Caniego-Casas T; Molecular Pathology of Cancer Group, Ramón y Cajal Health Research Institute (IRYCIS), 28034, Madrid, Spain.
  • Sarrió D; Centre for Biomedical Research in Cancer Networks (CIBERONC), Carlos III Health Institute, 28029, Madrid, Spain.
  • Moreno-Bueno G; Department of Pathology, Ramón y Cajal University Hospital, 28034, Madrid, Spain.
  • Gión M; Faculty of Medicine, University of Alcalá, 28801, Madrid, Spain.
  • Perez-García J; Molecular Pathology of Cancer Group, Ramón y Cajal Health Research Institute (IRYCIS), 28034, Madrid, Spain.
  • Cortés J; Centre for Biomedical Research in Cancer Networks (CIBERONC), Carlos III Health Institute, 28029, Madrid, Spain.
  • Smolkova B; Department of Pathology, Ramón y Cajal University Hospital, 28034, Madrid, Spain.
  • Palacios J; Faculty of Medicine, University of Alcalá, 28801, Madrid, Spain.
Virchows Arch ; 2024 May 07.
Article em En | MEDLINE | ID: mdl-38713384
ABSTRACT
The proposed role of CDH1 (E-cadherin gene) methylation as a mechanism of gene inactivation in invasive lobular carcinoma (ILC) remains inconclusive. For many years, CDH1 promoter hypermethylation has been regarded as a mechanism for gene inactivation in ILC. However, this assumption has primarily relied on non-quantitative assays, which have reported CDH1 methylation frequencies ranging from 26 to 93% at CpG sites within the island region. Few studies employing quantitative methods and covering CpG island shores, regions of relatively low CpG density situated proximal to conventional promoter CpGs, have been conducted, revealing lower percentages of methylation ranging from 0 to 51%. Therefore, using the quantitative pyrosequencing method, we examined CDH1 methylation in the island region and shores in E-cadherin deficient ILC cases (15 with CDH1 mutation and 22 non-mutated), 19 cases of invasive breast carcinomas non-special type (IBC-NSTs), and five cases of usual ductal hyperplasia (UDH). Our analysis revealed CDH1 methylation frequencies ranging from 3 to 64%, with no significant increase in methylation levels in any group of ILCs (median = 12%) compared to IBC-NST (median = 15%). In addition, considering the poorly studied association between the number of tumor-infiltrating lymphocytes (TILs) and CDH1 methylation in breast cancer, we undertook a thorough analysis within our dataset. Our findings revealed a positive correlation between CDH1 methylation and the presence of TILs (r = 0.5; p-value < 0.05), shedding light on an aspect of breast cancer biology warranting further investigation. These findings challenge CDH1 methylation as a CDH1 inactivation mechanism in ILC and highlight TILs as a potential confounding factor in gene methylation.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article